Tamra Sami

Neurizon Therapeutics Ltd. has advanced NUZ-001 (monepantel) from a 12-patient proof-of-concept study into a fully enrolled, 250-patient amyotrophic lateral sclerosis (ALS) trial that the U.S. FDA has indicated could potentially serve as the single registrational study supporting an NDA. The Australian biotech expects the pivotal readout in the second quarter of 2027.

Seven months after putting $920 million on the table for Aicuris Anti-infective Cures AG, Asahi Kasei Therapeutics Inc. has converted the German biotech's lead asset into an FDA-approved product. The FDA approved Hovilpri (pritelivir) to treat mucocutaneous lesions caused by herpes simplex virus infection that is refractory – with or without documented resistance – to acyclovir, valacyclovir or famciclovir in immunocompromised adults.

Neurizon Therapeutics Ltd. has advanced NUZ-001 (monepantel) from a 12-patient proof-of-concept study into a fully enrolled, 250-patient amyotrophic lateral sclerosis (ALS) trial that the U.S. FDA has indicated could potentially serve as the single registrational study supporting an NDA. The…

Syntara Ltd. reported additional phase II data supporting development of SNT-4728 as a potential disease-modifying therapy for Parkinson's disease, with patients at high risk of developing the neurodegenerative disorder showing statistically significant improvements in clinician-assessed motor function months after treatment ended.

Two phase III successes have delivered validation for Bristol Myers Squibb Co. across two strategically important programs, although limited top-line disclosures leave the magnitude of both wins and the competitive position of the assets unclear.

Takeda Pharmaceutical Co. Ltd. has quantified the potential convenience advantage of its 20% facilitated subcutaneous immunoglobulin, TAK-881, reporting comparable IgG exposure to its Hyqvia with half the infusion volume and a 42.6% shorter median administration time when each treatment was delivered through one site.

A decade ago, Amanda Randles and her colleagues could use a supercomputer to simulate only a few heartbeats through a patient's cardiovascular anatomy. Duke University researchers now believe they have the mathematics and computing methods needed to reconstruct as much as a year of patient-specific blood flow using data from wearables and other sensors to show how cardiovascular conditions change during daily life.

Life sciences investors are raising billions of dollars in fresh capital, with a cluster of new funds and acquisition vehicles positioning specialist firms for more biotech company formation and financing. China’s increasingly productive drug-development sector is a key part of that investment…

Australia must make biotechnology a strategic national industry and build on its clinical trial strengths as political pressure on U.S. scientific institutions and China's rise reshape global drug development, industry veteran Jeremy Levin told the Ausbiotech International Conference on Queensland's Gold Coast Oct. 21.

The next breakthrough in artificial intelligence-driven drug discovery may depend less on more sophisticated algorithms than on unlocking decades of experimental data held by pharma companies and research institutes, Australian biotech pioneer Andrew Wilks told delegates at the AusBiotech International Conference in Queensland this week.